Suppr超能文献

纤溶酶原激活物抑制剂活性增加及糖尿病可预测心绞痛患者随后的冠状动脉事件。

Increased plasminogen activator inhibitor activity and diabetes predict subsequent coronary events in patients with angina pectoris.

作者信息

Takazoe K, Ogawa H, Yasue H, Sakamoto T, Soejima H, Miyao Y, Kawano H, Moriyama Y, Misumi K, Suefuji H, Kugiyama K, Yoshimura M

机构信息

Department of Cardiovascular Medicine, Kumamoto University School of Medicine, Japan.

出版信息

Ann Med. 2001 Apr;33(3):206-12. doi: 10.3109/07853890109002079.

Abstract

BACKGROUND

Plasminogen activator inhibitor (PAI) is a marker of recurrence of myocardial infarction. Diabetes mellitus is also an important risk factor of coronary artery disease, including myocardial infarction and angina pectoris.

AIM

We examined baseline plasma PAI activity levels, clinical variables, and angiographic findings and assessed them as prospective values for subsequent coronary events, such as sudden death, nonfatal myocardial infarction and coronary revascularization by percutaneous transluminal coronary angioplasty or coronary artery bypass surgery during the follow-up period.

METHODS

We conducted a prospective study for 4 years of 249 consecutive patients admitted with angina pectoris. Blood samples for PAI were drawn at discharge.

RESULTS

In the multivariate Cox proportional hazard model, PAI activity and diabetes mellitus were significant and independent risk factors (the risk increased by 10% in those with a higher PAI concentration and by 70% in diabetic patients). Event-free survival was reduced by higher PAI activity (> or = 8.4 IU/mL) and the presence of diabetes. The patients with higher PAI activity and diabetes had a 4.2-fold risk in comparison with the patients with lower PAI activity and no diabetes. However, patients with lower PAI activity were less likely to have coronary events even when they had diabetes.

CONCLUSIONS

Higher PAI activity and diabetes predict subsequent coronary events in patients with angina pectoris. Diabetes has less prognostic value for subsequent coronary events in patients with lower PAI activity.

摘要

背景

纤溶酶原激活物抑制剂(PAI)是心肌梗死复发的一个标志物。糖尿病也是冠状动脉疾病(包括心肌梗死和心绞痛)的一个重要危险因素。

目的

我们检测了基线血浆PAI活性水平、临床变量及血管造影结果,并将它们评估为后续冠状动脉事件(如随访期间的猝死、非致命性心肌梗死以及经皮腔内冠状动脉成形术或冠状动脉搭桥手术进行的冠状动脉血运重建)的预测指标。

方法

我们对249例因心绞痛入院的连续患者进行了为期4年的前瞻性研究。在出院时采集PAI血样。

结果

在多变量Cox比例风险模型中,PAI活性和糖尿病是显著且独立的危险因素(PAI浓度较高者风险增加10%,糖尿病患者风险增加70%)。较高的PAI活性(≥8.4 IU/mL)和糖尿病的存在使无事件生存期缩短。与PAI活性较低且无糖尿病的患者相比,PAI活性较高且患有糖尿病的患者风险高4.2倍。然而,即使患有糖尿病,PAI活性较低的患者发生冠状动脉事件的可能性也较小。

结论

较高的PAI活性和糖尿病可预测心绞痛患者后续的冠状动脉事件。对于PAI活性较低的患者,糖尿病对后续冠状动脉事件的预后价值较小。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验